Analysts Set Tenax Therapeutics, Inc. (NASDAQ:TENX) Target Price at $16.00

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) have received an average recommendation of “Buy” from the five brokerages that are presently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $16.00.

Several research analysts recently commented on the company. StockNews.com started coverage on Tenax Therapeutics in a research note on Thursday, September 26th. They issued a “sell” rating for the company. Guggenheim started coverage on Tenax Therapeutics in a report on Monday, October 14th. They issued a “buy” rating and a $16.00 target price for the company. Leerink Partners started coverage on Tenax Therapeutics in a report on Thursday, October 24th. They issued an “outperform” rating and a $16.00 target price for the company. Leerink Partnrs upgraded Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. Finally, William Blair started coverage on Tenax Therapeutics in a report on Monday, September 30th. They issued an “outperform” rating for the company.

Tenax Therapeutics Price Performance

NASDAQ TENX opened at $4.85 on Tuesday. The business has a fifty day moving average price of $4.08 and a 200 day moving average price of $3.72. Tenax Therapeutics has a one year low of $2.77 and a one year high of $33.44.

Hedge Funds Weigh In On Tenax Therapeutics

Hedge funds have recently modified their holdings of the business. Sphera Funds Management LTD. purchased a new position in shares of Tenax Therapeutics during the 3rd quarter worth $101,000. Stonepine Capital Management LLC purchased a new position in shares of Tenax Therapeutics during the 3rd quarter worth $173,000. Finally, Vestal Point Capital LP purchased a new position in shares of Tenax Therapeutics during the 3rd quarter worth $288,000. 1.67% of the stock is currently owned by hedge funds and other institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.